HEREDITARY ANGIOEDEMA TREATMENT MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

  2024-11-27 |   Pages: 200+ |   Report ID: MD-R-2024-11-27-39193 |   Healthcare

Historical data: 2018 - 2023

Forecast period: 2024 - 2031

Quantitative units: Revenue in USD million and CAGR from 2024 to 2031

Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Hereditary Angioedema Treatment Market

Image

1.1 SCOPE OF THE REPORT

1.2 MARKET SEGMENT ANALYSIS

1.3 REGULATORY SCENARIO BY REGION/COUNTRY

1.4 MARKET INVESTMENT SCENARIO STRATEGIC

1.5 MARKET ANALYSIS BY TYPE (USD MILLION)

1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL HEREDITARY ANGIOEDEMA TREATMENT MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL HEREDITARY ANGIOEDEMA TREATMENT MARKET

7.1 GLOBAL HEREDITARY ANGIOEDEMA TREATMENT MARKET SIZE AND SHARE (2018-2031) (USD MILLION)

8.1 GLOBAL HEREDITARY ANGIOEDEMA TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

8.2 GLOBAL HEREDITARY ANGIOEDEMA TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

9.1 GLOBAL HEREDITARY ANGIOEDEMA TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

9.2 GLOBAL HEREDITARY ANGIOEDEMA TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

10.1 GLOBAL HEREDITARY ANGIOEDEMA TREATMENT MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)

10.2 GLOBAL HEREDITARY ANGIOEDEMA TREATMENT MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)

11.1 NORTH AMERICA HEREDITARY ANGIOEDEMA TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

11.2 NORTH AMERICA HEREDITARY ANGIOEDEMA TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

11.3 NORTH AMERICA HEREDITARY ANGIOEDEMA TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

11.4 NORTH AMERICA HEREDITARY ANGIOEDEMA TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

11.5 NORTH AMERICA HEREDITARY ANGIOEDEMA TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

11.6 NORTH AMERICA HEREDITARY ANGIOEDEMA TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

12.1 EUROPE HEREDITARY ANGIOEDEMA TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

12.2 EUROPE HEREDITARY ANGIOEDEMA TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

12.3 EUROPE HEREDITARY ANGIOEDEMA TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

12.4 EUROPE HEREDITARY ANGIOEDEMA TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

12.5 EUROPE HEREDITARY ANGIOEDEMA TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

12.6 EUROPE HEREDITARY ANGIOEDEMA TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

13.1 ASIA PACIFIC HEREDITARY ANGIOEDEMA TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

13.2 ASIA PACIFIC HEREDITARY ANGIOEDEMA TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

13.3 ASIA PACIFIC HEREDITARY ANGIOEDEMA TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

13.4 ASIA PACIFIC HEREDITARY ANGIOEDEMA TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

13.5 ASIA PACIFIC HEREDITARY ANGIOEDEMA TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

13.6 ASIA PACIFIC HEREDITARY ANGIOEDEMA TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

14.1 LATIN AMERICA HEREDITARY ANGIOEDEMA TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>

14.2 LATIN AMERICA HEREDITARY ANGIOEDEMA TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

14.3 LATIN AMERICA HEREDITARY ANGIOEDEMA TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

14.4 LATIN AMERICA HEREDITARY ANGIOEDEMA TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

14.5 LATIN AMERICA HEREDITARY ANGIOEDEMA TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

14.6 LATIN AMERICA HEREDITARY ANGIOEDEMA TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>

16.1 Shire plc (Takeda Pharmaceutical Company Limited)

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 CSL Limited

16.3 Pharming Group N.V.

16.4 Ionis Pharmaceuticals, Inc.

16.5 BioCryst Pharmaceuticals, Inc.

16.6 KalVista Pharmaceuticals Ltd.

16.7 Attune Pharmaceuticals

16.8 Arrowhead Pharmaceuticals,Inc

16.9 Adervum

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER

Market Segments

By Drug Class
C1 Esterase Inhibitor
  o Plasma Products
     o Berinert
     o Cinryze
     o Haegarda
  o Recombinant Products
     o Ruconest
Selective Bradykinin B2 Receptor Antagonist
  o Firazyr
Kallikrein Inhibitor
  o Kalbitor
  o Takhzyro
Others
  o Conventional Drugs
  o Pipeline Drugs

By Application
Prophylaxis
Treatment

By Route of Administration
Intravenous
Subcutaneous Injection
Oral

By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others

Companies

Shire plc (Takeda Pharmaceutical Company Limited)
CSL Limited
Pharming Group N.V.
Ionis Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc.
KalVista Pharmaceuticals Ltd.
Attune Pharmaceuticals
Arrowhead Pharmaceuticals,Inc
Adervum

Single User License  : 3900$
Corporate License    : 7800$
Enquiry Before Buying
Request For Customization
Speak To Analyst

BROWSE INDUSTRY

  1. Consumer Goods
  2. Healthcare
  3. Food & Beverage
  4. Heavy Industry
  5. Service Industries
  6. FMCG
  7. Life Sciences
  8. Technology & Media
  9. Machinery & Equipment

    WHY CHOOSE US

  •   PROACTIVE

    • We manage our resources 24/7 to identify issues and address them before they become problems.

  •   QUALITY & RELIABILITY

    • We are committed to providing reliable and highly accurate data with an excellent quality control system.

  •   GLOBAL OUTREACH

    • 6 Major regions and 40+ countries level analysis accomplished.

  •   COMPETITIVE PRICING

    • Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.